Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Rijckborst, Vincent; Hansen, Bettina; Ferenci, Peter; Brunetto, Maurizia; Tabak, ÖMER; Cakaloglu, Yilmaz; Lanza, A.; Messina, Vincenzo; Iannacone, Claudio; Massetto, Benedetta; Regep, Loredana; Colombo, Massimo; Janssen, Harry; Lampertico, Pietro

doi:10.1016/j.jhep.2011.12.007

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Rijckborst V., Hansen B. E., Ferenci P., Brunetto M. R., Tabak F., Cakaloglu Y., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.56, sa.5, ss.1006-1011, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 56 Sayı: 5
Basım Tarihi: 2012
Doi Numarası: 10.1016/j.jhep.2011.12.007
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1006-1011
Anahtar Kelimeler: HBV therapy, Immunomodulator, Nucleos(t)ide analogues, Peginterferon, Quantitative HBsAg, HBV genotype, CHRONIC HEPATITIS-B, SUSTAINED RESPONSE, LAMIVUDINE, ENTECAVIR, GENOTYPE
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with <2 log hepatitis B virus (HBV) DNA decline at week 12 of a 48-week peginterferon alfa-2a (PEG-IFN) treatment course achieved a sustained response (SR). We aimed at validating this stopping rule in two independent trials.